Rockefeller Capital Management
CORT icon

Rockefeller Capital Management’s Corcept Therapeutics CORT Stock Holding History

Rockefeller Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.98M Buy
123,497
+57,700
+88% +$2.16M 0.01% 917
2025
Q4 		$2.29M Buy
65,797
+53,574
+438% +$4.21M ﹤0.01% 1191
2025
Q3 		$1.02M Buy
+12,223
New +$885K ﹤0.01% 1421
2023
Q1 		– Sell
-38
Closed – – 2348
2022
Q4 		$0 Hold
38
– – ﹤0.01% 3892
2022
Q3 		$0 Sell
38
-193
-84% -$5.17K ﹤0.01% 3942
2022
Q2 		$5K Buy
+231
New +$5.03K ﹤0.01% 3431
2021
Q1 		– Sell
-5
Closed – – 3263
2020
Q4 		$0 Buy
+5
New +$105 ﹤0.01% 2870

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Rockefeller Capital Management's CORT Position: Q1 2026 in Review

Rockefeller Capital Management increased its Corcept Therapeutics (CORT) stake by 88% in Q1 2026, buying an estimated $2.16M and bringing the position to 123,497 shares worth $4.98M. The position accounts for 0.01% of the portfolio, ranked #917.

Rockefeller Capital Management first reported a position in CORT in Q4 2020 and has held it in 7 quarters since. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Rockefeller Capital Management held 123,497 shares of Corcept Therapeutics worth $4.98M as of Q1 2026.
  • Rockefeller Capital Management bought 57,700 Corcept Therapeutics shares in Q1 2026, an estimated $2.16M.
  • Corcept Therapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #917 holding.
  • Rockefeller Capital Management first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 7 quarters since.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.